Impairment and disability in 20 CIDP patients according to disease activity status

Journal of the Peripheral Nervous System

Volumn 18, Issue 3, 2013, Pages 241-246

  Panaite, Petrica Adrian ^a   Renaud, Susanne ^a,b   Kraftsik, Rudolf ^c   Steck, Andreas J ^a,d   Kuntzer, Thierry ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Hopital Neuchatelois   (Switzerland)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

CDAS; CIDP; grading systems; R ODS; scores

Indexed keywords

ADULT; AGED; CLINICAL ARTICLE; CONFERENCE PAPER; DISABILITY; DISEASE ACTIVITY; DISEASE DURATION; FEMALE; HUMAN; MALE; POLYRADICULONEUROPATHY; PRIORITY JOURNAL; SCORING SYSTEM;

CDAS; CIDP; GRADING SYSTEMS; R-ODS; SCORES;

ADULT; AGED; COHORT STUDIES; DISABILITY EVALUATION; DISABLED PERSONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; PRINCIPAL COMPONENT ANALYSIS; SEVERITY OF ILLNESS INDEX;

EID: 84884396496     PISSN: 10859489     EISSN: 15298027     Source Type: Journal    
DOI: 10.1111/jns5.12038     Document Type: Conference Paper

References (16)

1. Dyck PJ, Sherman WR, Hallcher LM, Service FJ, O'Brien PC, Grina LA, Palumbo PJ, Swanson CJ, (1980). Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry. Ann Neurol 8: 590-596.
2. Dyck PJ, O'Brien PC, Oviatt KF, Dinapoli RP, Daube JR, Bartleson JD, Mokri B, Swift T, Low PA, Windebank AJ, (1982). Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 11: 136-141.
3. Dyck PJ, Boes CJ, Mulder D, Millikan C, Windebank AJ, Dyck PJ, Espinosa R, (2005). History of standard scoring, notation, and summation of neuromuscular signs. A current survey and recommendation. J Peripher Nerv Syst 10: 158-173.
4. Gorson KC, van Schaik IN, Merkies IS, Lewis RA, Barohn RJ, Koski CL, Cornblath DR, Hughes RA, Hahn AF, Baumgarten M, Goldstein J, Katz J, Graves M, Parry G, van Doorn PA, (2010). Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice. J Peripher Nerv Syst 15: 326-333.
5. Herndon RM, (2005). Peripheral neuropathy and pain scales. In: Handbook of Neurologic Rating Scales., Herndon RM, (Ed). Demos Medical Publishing, New York, pp 285-296.
6. Hughes R, Bensa S, Willison H, Van den Bergh P, Comi G, Illa I, Nobile-Orazio E, van DP, Dalakas M, Bojar M, Swan A, Inflammatory Neuropathy Cause and Treatment (INCAT) Group (2001). Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 50: 195-201.
7. Hughes RA, Donofrio P, Bril V, Dalakas MC, Deng C, Hanna K, Hartung HP, Latov N, Merkies IS, van Doorn PA, (2008). Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 7: 136-144.
8. Joint Task Force of the EFNS and the PNS (2010). European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society-first revision. J Peripher Nerv Syst 15: 1-9.
9. Mendell JR, Barohn RJ, Freimer ML, Kissel JT, King W, Nagaraja HN, Rice R, Campbell WW, Donofrio PD, Jackson CE, Lewis RA, Shy M, Simpson DM, Parry GJ, Rivner MH, Thornton CA, Bromberg MB, Tandan R, Harati Y, Giuliani MJ, Working Group on Peripheral Neuropathy (2001). Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 56: 445-449.
10. Merkies IS, Schmitz PI, Samijn JP, van der Meche FG, van Doorn PA, (1999). Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology 53: 1648-1654.
11. Merkies IS, Schmitz PI, van der Meche FG, van Doorn PA, (2000). Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology 54: 943-949.
12. Merkies IS, Schmitz PI, van der Meche FG, Samijn JP, van Doorn PA, (2002). Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry 72: 596-601.
13. van Nes SI, Vanhoutte EK, van Doorn PA, Hermans M, Bakkers M, Kuitwaard K, Faber CG, Merkies IS, (2011). Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies. Neurology 76: 337-345.
14. SAS Institute Inc (2012). analyzing principal components and reducing dimensionality. In: JMP® 10 Modeling and Multivariate Methods. SAS Institute Inc, Cary, NC, pp 489-498.
15. van Schaik IN, Eftimov F, van Doorn PA, Brusse E, van den Berg LH, van der Pol WL, Faber CG, van Oostrom JC, Vogels OJ, Hadden RD, Kleine BU, van Norden AG, Verschuuren JJ, Dijkgraaf MG, Vermeulen M, (2010). Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol 9: 245-253.
16. Scott OM, Hyde SA, Goddard C, Dubowitz V, (1982). Quantitation of muscle function in children: a prospective study in Duchenne muscular dystrophy. Muscle Nerve 5: 291-301.